Canaccord Genuity Starts coverage with $3 Speculative Buy Rating for Khiron Life Sciences

Khiron Life Sciences Corp. (TSXV:KHRN) was featured in a speculative buy report by Canaccord Genuity, an independent full-service financial services firm. The basis for the report was based on Khiron’s first mover advantage and the emerging legalized cannabis markets in Latin America.

Khiron operates out of Colombia, which offers optimal growing conditions, cost advantages, liberal prescribing regulations and a medical cannabis market comprised of approximately 700,000 patients. The report concluded, that the Latin American cannabis market has a potential to make $8 to $9 billion annually. The report highlighted Khiron’s facilities in Colombia, which will be able to produce approximately 16,900 kilograms of cannabis per year and will be able to service approximately 100,000 patients. The company is expecting its first harvest in late 2018 and expects sales to commence in early 2019.

The report also touched on Khiron’s established medical cannabis patient network of approximately 400,000 patients. Their patient base has been developed through their education platform and their strategic alliances with 3,000 doctors. The company is also in the process of closing an acquisition for the ILANS clinics, which could bring an additional 100,000 patients to its portfolio. The first clinic is expected to be operational by the end of 2018 depending on the closing of the acquisition.

These two factors, among others, provided the basis for the report’s $3 speculative buy rating.

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN) for an Investor Presentation.

Source: canaccordgenuity.bluematrix.com